» Articles » PMID: 20472887

Tissue Slice Grafts: an in Vivo Model of Human Prostate Androgen Signaling

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2010 May 18
PMID 20472887
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We developed a tissue slice graft (TSG) model by implanting thin, precision-cut tissue slices derived from fresh primary prostatic adenocarcinomas under the renal capsule of immunodeficient mice. This new in vivo model not only allows analysis of approximately all of the cell types present in prostate cancer within an intact tissue microenvironment, but also provides a more accurate assessment of the effects of interventions when tissues from the same specimen with similar cell composition and histology are used as control and experimental samples. The thinness of the slices ensures that sufficient samples can be obtained for large experiments as well as permits optimal exchange of nutrients, oxygen, and drugs between the grafted tissue and the host. Both benign and cancer tissues displayed characteristic histology and expression of cell-type specific markers for up to 3 months. Moreover, androgen-regulated protein expression diminished in TSGs after androgen ablation of the host and was restored after androgen repletion. Finally, many normal secretory epithelial cells and cancer cells in TSGs remained viable 2 months after androgen ablation, consistent with similar observations in postprostatectomy specimens following neoadjuvant androgen ablation. Among these were putative Nkx3.1(+) stem cells. Our novel TSG model has the appropriate characteristics to serve as a useful tool to model all stages of disease, including normal tissue, premalignant lesions, well-differentiated cancer, and poorly differentiated cancer.

Citing Articles

Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues.

Polasko A, Zhang D, Ramraj A, Chiu C, Garcia-Marques F, Bermudez A Lab Invest. 2024; 104(10):102129.

PMID: 39222914 PMC: 11502252. DOI: 10.1016/j.labinv.2024.102129.


Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma.

Piraquive Agudelo J, Upadhyay D, Zhang D, Zhao H, Nolley R, Sun J Metabolites. 2022; 12(11).

PMID: 36422257 PMC: 9692472. DOI: 10.3390/metabo12111117.


Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.

Wang J, Liu X, Ji J, Luo J, Zhao Y, Zhou X Front Immunol. 2022; 13:863346.

PMID: 35874730 PMC: 9302770. DOI: 10.3389/fimmu.2022.863346.


Harnessing the Utility of Patient Prostate Tissue Slice Cultures.

Perez L, Nonn L Front Oncol. 2022; 12:864723.

PMID: 35433436 PMC: 9008363. DOI: 10.3389/fonc.2022.864723.


Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.

Patierno B, Foo W, Allen T, Somarelli J, Ware K, Gupta S Prostate Cancer Prostatic Dis. 2021; 25(3):513-523.

PMID: 34645983 PMC: 9005588. DOI: 10.1038/s41391-021-00460-y.


References
1.
Lei Q, Jiao J, Xin L, Chang C, Wang S, Gao J . NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006; 9(5):367-78. DOI: 10.1016/j.ccr.2006.03.031. View

2.
Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

3.
Lamb D, Zhang L . Challenges in prostate cancer research: animal models for nutritional studies of chemoprevention and disease progression. J Nutr. 2005; 135(12 Suppl):3009S-3015S. DOI: 10.1093/jn/135.12.3009S. View

4.
Wang X, Kruithof-de Julio M, Economides K, Walker D, Yu H, Halili M . A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461(7263):495-500. PMC: 2800362. DOI: 10.1038/nature08361. View

5.
de Jong I, Eaton A, Bladou F . LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin. 2007; 23(5):1077-80. DOI: 10.1185/030079907x187973. View